Inovio

Inovio's stock gains on early data testing its COVID-19 vaccine in animals

Shares of Inovio INO, +2.75% gained 22.8% in premarket trading on Wednesday after the company said its COVID-19 vaccine candidate demonstrated neutralizing antibodies in animals. The data, published in Nature Communications, is from a preclinical study, meaning it does not include information about how the investigational vaccine reacts in humans but in mice and guinea pigs. Inovio is currently conducting a Phase 1 clinical trial testing the DNA vaccine candidate in people; early data from that study is expected to be announced in June.

...

https://www.marketwatch.com/story/inovio...latestnews

Inovio Stock Tumbles After Covid-19 Vaccine Trial Is Halted

The technology used by Inovio Pharmaceuticals for its experimental vaccine against Covid-19 is distinct from its better-known rivals. On Monday, Inovio said that the U.S. Food and Drug Administration had put the company’s vaccine trial on hold, until the company resolves the agency’s questions about Inovio’s vaccine technology.

...


https://www.barrons.com/articles/inovio-...eid=yhoof2